Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irradiated MMC10-BCSC whole tumor cell vaccine is an experimental preclinical cancer vaccine derived from breast cancer stem-like cells (BCSC) of the mouse mammary carcinoma (MMC) sub-line MMC10. Developed by researchers at The Cleveland Clinic, the vaccine is designed to stimulate an immune response against HER2/neu-positive breast cancer. In preclinical models, vaccination with irradiated MMC10-BCSCs primes CD4+ and CD8+ T cells, which can be harvested and expanded in vitro to mediate the regression of established pulmonary metastases upon adoptive transfer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irradiated MMC10-BCSC whole tumor cell vaccine.